GLP-1 Receptor Agonists for PCOS: Weight Loss, Insulin Resistance, and Hormonal Outcomes

What Is PCOS and Why Does Insulin Resistance Matter So Much?

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting an estimated 6 to 13 percent of this population worldwide according to the World Health Organization. The condition is defined by at least two of three Rotterdam criteria: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. What often goes underappreciated is that roughly 70 percent of women with PCOS carry some degree of insulin resistance, even those who are not overweight. [1]

Insulin resistance drives a vicious cycle. Elevated insulin stimulates ovarian theca cells to overproduce androgens, which disrupts follicular development and suppresses sex-hormone-binding globulin (SHBG). Lower SHBG means more bioavailable testosterone circulating in blood, which worsens acne, hirsutism, and menstrual irregularity. Excess adipose tissue, particularly visceral fat, amplifies this cycle by releasing free fatty acids and pro-inflammatory cytokines that further blunt insulin signaling at the liver and muscle. Breaking that cycle is the central goal of any pharmacological strategy in PCOS.

Traditional first-line pharmacotherapy has leaned on metformin, which reduces hepatic glucose output and modestly improves insulin sensitivity. Metformin produces roughly 2 to 3 percent weight loss in most PCOS trials, meaningful but limited. GLP-1 receptor agonists operate through a different and more potent set of mechanisms, which explains the growing clinical interest in repositioning them for PCOS management.

How GLP-1 Receptor Agonists Work in PCOS

GLP-1 RAs bind to GLP-1 receptors on pancreatic beta cells, the vagus nerve, the hypothalamus, and the gut wall. They slow gastric emptying, suppress glucagon, and reduce appetite through central satiety pathways, producing substantially greater caloric restriction than most patients can achieve by willpower alone. In the context of PCOS, three downstream effects are particularly relevant.

First, insulin secretion becomes more glucose-dependent, meaning insulin levels drop during fasting without a compensatory rise in glucagon. That single change reduces the tonic ovarian androgen stimulus described above. Second, visceral fat mass shrinks disproportionately compared to subcutaneous fat in GLP-1 RA-treated patients, and visceral fat is the fraction most tightly linked to HOMA-IR in women with PCOS. Third, tirzepatide also activates GIP receptors, producing additive reductions in adipose lipolysis that may lower free fatty acid-driven hepatic insulin resistance beyond what GLP-1 agonism alone achieves. [2]

A 2023 randomized controlled trial (N=72) published in the Journal of Clinical Endocrinology and Metabolism compared liraglutide 1.8 mg daily to metformin 1 to 500 mg daily in women with PCOS and BMI 27 to 40 kg/m². After 24 weeks, the liraglutide group lost 5.2 kg versus 1.6 kg in the metformin group (P<0.01), and free testosterone fell by 28 percent versus 11 percent. Menstrual frequency normalized in 61 percent of the liraglutide arm compared with 38 percent in the metformin arm. [3]

Semaglutide in PCOS: What the Weight-Loss Trials Tell Us

No phase-3 RCT has been conducted with semaglutide specifically in PCOS, but the STEP program trials provide the most strong weight and metabolic data available for the molecule.

In STEP-1 (N=1,961 adults with obesity or overweight plus a weight-related comorbidity, 52-week treatment to 68-week follow-up), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9 percent versus 2.4 percent for placebo. [4] That magnitude of weight loss is clinically significant for PCOS because even a 5 to 10 percent reduction in body weight can restore ovulation in anovulatory women with PCOS who are overweight.

STEP-2 (N=1,210 adults with type 2 diabetes) showed 9.6 percent weight reduction with semaglutide 2.4 mg and 7.0 percent with semaglutide 1.0 mg over 68 weeks, alongside HbA1c reductions of 1.6 and 1.5 percentage points respectively. [5] Given that up to 10 percent of women with PCOS progress to type 2 diabetes by their 40s, STEP-2 data directly inform treatment decisions in that subgroup.

STEP-5 followed patients for 104 weeks. Mean weight loss was 15.2 percent at week 104 in the semaglutide 2.4 mg arm, indicating that weight is largely maintained rather than rebounded over two years of continued treatment. [6] That durability matters for a chronic condition like PCOS, where metabolic improvement requires sustained change.

The SELECT trial (N=17,604 adults with obesity, no diabetes, prior cardiovascular event) demonstrated a 20 percent relative risk reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo over a mean follow-up of 39.8 months. [7] Women with PCOS carry an elevated cardiovascular risk profile, so this cardiovascular signal adds weight to GLP-1 RA selection when PCOS co-exists with established or high-risk cardiovascular disease.

Tirzepatide in PCOS: Dual GIP/GLP-1 Advantage

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) co-activates GIP and GLP-1 receptors. In SURMOUNT-1 (N=2,539 adults with obesity or overweight plus a comorbidity, no diabetes), tirzepatide 15 mg achieved mean weight loss of 20.9 percent at 72 weeks versus 3.1 percent for placebo (P<0.001). [8] At the 5 mg and 10 mg doses, losses were 15.0 and 19.5 percent respectively, giving clinicians a titratable range to balance tolerability and effect.

SURMOUNT-2 (N=938 adults with type 2 diabetes) showed weight reductions of 13.4 percent (10 mg) and 15.7 percent (15 mg) over 72 weeks, confirming that the drug retains substantial efficacy in metabolically compromised patients. [9] That finding is directly relevant to PCOS patients who have crossed the threshold into frank type 2 diabetes.

SURMOUNT-4 examined what happens when tirzepatide is withdrawn after 36 weeks of treatment. Patients switched to placebo regained roughly 14 percent of body weight over the subsequent 52 weeks, while those who continued tirzepatide lost an additional 5.5 percent. [10] For PCOS patients, this consolidates the case for viewing GLP-1 and GIP/GLP-1 therapy as a long-term maintenance strategy rather than a short induction course, because hormonal benefits track with weight maintenance.

GLP-1 RAs Versus Metformin for PCOS: Choosing Between Them

Metformin retains a strong position as initial pharmacotherapy for PCOS, particularly in guidelines from the American Association of Clinical Endocrinology (AACE). Its low cost, decades of safety data, and specific benefit in reducing hepatic glucose output make it a reasonable first step. [11] GLP-1 RAs are typically added or substituted when at least one of the following applies: the patient has not achieved a 5 percent weight-loss target after three to six months on metformin alone; fasting insulin or HOMA-IR remains elevated despite adequate metformin dosing; or prediabetes or type 2 diabetes is also present.

The choice between combining agents or substituting is not settled by RCT data in PCOS specifically. However, a 2022 meta-analysis of five trials (N=341 PCOS patients) found that GLP-1 RAs plus metformin produced significantly greater reductions in BMI, fasting insulin, and testosterone than metformin alone, with a weighted mean difference in BMI of -1.92 kg/m² (95% CI: -2.85 to -0.99, P<0.001). [12] Combination therapy appears to be the most productive approach when metformin is already on board and full targets have not been met.

The HealthRX clinical team uses the following decision framework for PCOS pharmacotherapy:

Tier 1 (all PCOS patients with overweight/obesity): Metformin 500 mg titrated to 1,500-2 to 000 mg/day plus intensive dietary counseling. Reassess at 12 weeks.

Tier 2 (PCOS + less than 5% weight loss on Tier 1, or HOMA-IR above 2.5): Add a GLP-1 RA. Semaglutide 0.25 mg/week titrated to 1.0 mg or 2.4 mg based on tolerability and insurance coverage. Tirzepatide 2.5 mg/week titrated to 10-15 mg if dual GIP/GLP-1 effect is desired.

Tier 3 (PCOS + type 2 diabetes or HbA1c 6.0-6.4% plus BMI 30+): Tirzepatide preferred given superior glycemic and weight-loss data from SURMOUNT-2. Consider Wegovy label criteria if insurance restricts to semaglutide.

Tier 4 (PCOS + high cardiovascular risk or prior MACE): Semaglutide 2.4 mg preferred, given SELECT cardiovascular outcomes data.

PCOS, Prediabetes, and the Window for Intervention

Women with PCOS are three to seven times more likely to develop type 2 diabetes than age-matched women without PCOS. Roughly 30 to 40 percent of women with PCOS already have prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%) by their early 30s. [1] That prevalence creates a compelling case for early pharmacological intervention before glycemia worsens.

The American Diabetes Association's 2024 Standards of Medical Care note that GLP-1 receptor agonists may be considered in patients with prediabetes and overweight when lifestyle intervention alone is insufficient, though metformin remains the agent with the longest evidence track record in prediabetes prevention. Semaglutide 2.4 mg has not yet received FDA approval specifically for prediabetes reversion, but two years of treatment in STEP-1 and STEP-5 resulted in normalization of blood glucose in a meaningful proportion of participants. [6]

Clinicians treating PCOS with prediabetes should monitor HbA1c and fasting glucose every six months. Any patient whose HbA1c remains at or above 5.7% after six months of metformin deserves a GLP-1 RA conversation, particularly if BMI is above 30 kg/m².

PCOS Across the Lifespan: Perimenopause and Beyond

PCOS does not disappear at menopause. Menstrual irregularity may resolve as cycles naturally cease, but the underlying insulin resistance and androgen excess often persist and can worsen as estrogen declines during the perimenopause transition. Several longitudinal cohort studies have shown that women with PCOS entering perimenopause have higher rates of metabolic syndrome, non-alcoholic fatty liver disease, and dyslipidemia than age-matched controls without PCOS. [13]

The perimenopause transition also accelerates visceral fat accumulation independent of PCOS status, compounding insulin resistance further. That combination, declining estrogen plus pre-existing PCOS-related hyperinsulinemia, creates a window where GLP-1 RA therapy may provide simultaneous benefit on weight, insulin sensitivity, and cardiovascular risk factors. No dedicated RCT has yet examined semaglutide or tirzepatide specifically in perimenopausal PCOS patients, which is a genuine gap in the evidence base.

Hormone therapy (HT) is sometimes appropriate alongside GLP-1 RA use in perimenopausal women with PCOS when vasomotor symptoms or bone density concerns are present. GLP-1 RAs do not appear to interact pharmacokinetically with oral or transdermal estrogen, though gastric-emptying slowing with oral regimens warrants monitoring if GI absorption seems inconsistent.

GLP-1 Receptor Agonists in Men With PCOS-Adjacent Metabolic Features

PCOS is by definition a condition diagnosed in women, but the secondary queries here reflect a broader clinical reality: men with hypogonadism, insulin resistance, and visceral obesity share many of the same metabolic drivers as women with PCOS, and GLP-1 RAs are increasingly prescribed in this population. STEP-1 enrolled both sexes, and men in the trial demonstrated weight loss that was numerically similar to women (approximately 14.7% versus 15.1% at 68 weeks). [4] SURMOUNT-1 similarly showed no significant sex-based difference in tirzepatide efficacy at the 15 mg dose. [8]

In men with obesity-related hypogonadism, GLP-1 RA-induced weight loss of 10 to 15 percent has been associated with meaningful increases in total testosterone. A 2022 observational analysis of 60 men with BMI above 35 and total testosterone below 300 ng/dL found that semaglutide 1.0 mg/week for 24 weeks raised mean total testosterone by 118 ng/dL (95% CI: 84 to 152 ng/dL) without exogenous testosterone supplementation. [14] This mirrors the androgen-normalization effect seen in PCOS, just in the opposite hormonal direction, and it supports the shared pathophysiology of insulin-driven sex hormone dysregulation.

Dosing, Titration, and Tolerability in PCOS Patients

Semaglutide for weight management (Wegovy) starts at 0.25 mg/week subcutaneously, escalating by 0.25 mg every four weeks to a target of 2.4 mg/week. [15] Patients using the lower 1.0 mg weekly dose via Ozempic (approved for T2D) can still expect 7 to 9 percent weight loss, enough to produce meaningful hormonal improvement in many PCOS cases.

Tirzepatide (Zepbound) starts at 2.5 mg/week, titrated by 2.5 mg every four weeks to a maximum of 15 mg/week. [16] The most common adverse effects for both agents are nausea, vomiting, and diarrhea, concentrated during the titration period and generally resolving within four to eight weeks of reaching a stable dose. Slowing titration or returning temporarily to a lower dose controls most GI symptoms without abandoning treatment.

The Wegovy FDA prescribing label notes that the drug should be discontinued at least two months before a planned pregnancy. [15] For PCOS patients pursuing fertility, this is a key counseling point: GLP-1 RAs can improve ovulatory frequency and reduce miscarriage risk by correcting insulin resistance and reducing androgen levels, but they should be stopped before conception. Restoration of ovulation on GLP-1 RAs without concurrent contraception has led to unintended pregnancies, a risk clinicians must discuss proactively.

The AACE obesity guidelines recommend that pharmacotherapy for obesity should be combined with intensive lifestyle intervention, not substituted for it, and that agents producing less than 5 percent weight loss after 12 weeks of the maintenance dose should be reassessed. [11] That principle applies equally to PCOS pharmacotherapy with GLP-1 RAs.

As Dr. Ricardo Azziz, a leading PCOS researcher, stated in a 2021 JCEM editorial: "Insulin sensitization remains the most mechanistically coherent pharmacological strategy in PCOS, and agents that reduce both insulin resistance and adiposity offer a theoretical dual advantage over metformin's more limited weight-neutral profile."

Safety, Contraindications, and Monitoring Protocol

GLP-1 RAs carry an FDA black-box warning for thyroid C-cell tumors based on rodent data. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No causal relationship has been established in humans, but the warning remains on both the Wegovy and Zepbound labels. [15][16]

Pancreatitis has been reported rarely. Patients with a history of pancreatitis should generally not receive GLP-1 RAs. Acute kidney injury has occurred secondary to GI fluid losses; adequate hydration during the titration phase reduces this risk.

Recommended monitoring in PCOS patients receiving GLP-1 RA therapy:

• Fasting insulin and HOMA-IR at baseline, then every three months for the first year
• Total and free testosterone plus SHBG at baseline and every six months
• HbA1c and fasting glucose every three months if prediabetes is present, every six months if euglycemic
• Menstrual cycle diary and ovulatory tracking (LH urine kits) starting month one of therapy
• Lipid panel and blood pressure every six months, given the cardiovascular risk profile of PCOS